$45 Neuropathy Relief Package (reg. $450) > SCHEDULE NOW < Click Here to
$45 Neuropathy Relief Package (reg. $450) > SCHEDULE NOW < Click Here to
$45 Neuropathy Relief Package (reg. $450) > SCHEDULE NOW < Click Here to
$45 Neuropathy Relief Package (reg. $450) > SCHEDULE NOW < Click Here to
Effect of deep tissue laser therapy treatment on peripheral neuropathic pain in older adults with type 2 diabetes: a pilot randomized clinical trial
BMC Geriatr
2019 Aug 12;19:218. doi: 10.1186/s12877-019-1237-5
Author
Prasun Chatterjee , Achal K Srivastava , Deepa A Kumar , Avinash Chakrawarty , Maroof A Khan , Akash K Ambashtha , Vijay Kumar , Luis De Taboada , Aparajit B Dey
Author Information
1Department of Geriatric Medicine, All India Institute of Medical Sciences, New Delhi, India
2Department of Neurology, All India Institute of Medical Sciences, New Delhi, India
3Department of Biostatistics, All India Institute of Medical Sciences, New Delhi, India
4Health World Hospital, Durgapur, West Bengal India
5LiteCure LLC, Carlsbad, CA USA
Article notes
Copyright and License information
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
PMC Copyright notice
PMCID: PMC6689877 PMID: 31405365
Abstract
Background
This study assessed the safety and efficacy of deep tissue laser therapy on the management of pain, functionality, systemic inflammation, and overall quality of life of older adults with painful diabetic peripheral neuropathy.
Methods
The effects of deep tissue laser therapy (DTLT) were assessed in a randomized, double-masked, sham-controlled, interventional trial. Forty participants were randomized (1:1) to receive either DTLT or sham laser therapy (SLT). In addition to the standard-of-care treatment, participants received either DTLT or SLT twice weekly for 4 weeks and then once weekly for 8 weeks (a 12-week intervention period). The two treatments were identical, except that laser emission was disabled during SLT. Assessments for pain, functionality, serum levels of inflammatory biomarkers, and quality of life (QOL) were performed at baseline and after the 12-week intervention period. The results from the two treatments were compared using ANOVA in a pre-test-post-test design.
Results
All participants randomized to the DTLT group and 85% (17 of 20) of participants randomized to the SLT group completed the trial. No significant differences in baseline characteristics between the groups were observed. After the 12-week intervention period, pain levels significantly decreased in both groups and were significantly lower in the DTLT group than in the SLT group. The Timed Up and Go test times (assessing functionality) were significantly improved in both groups and were 16% shorter in the DTLT group than in the SLT group. Serum levels of IL-6 decreased significantly in both groups. Additionally, serum levels of MCP-1 decreased significantly in the DTLT group but not in the SLT group. Patients’ quality of life improved significantly in the DTLT group but not in the SLT group.
Conclusions
Deep tissue laser therapy significantly reduced pain and improved the quality of life of older patients with painful diabetic peripheral neuropathy.
Trial registration
Clinical Trial Registry-India CTRI/2017/06/008739. [Registered on: 02/06/2017]. The trial was registered retrospectively.
Keywords: